Montelukast Aristo

Montelukast, the active ingredient in Montelukast Aristo, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Aristo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage respiratory allergic conditions.

- Asthma: improves long‑term control and reduces the frequency of bronchospasm. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: discomfort in the stomach region. - Cough: occasional dry cough. - Nausea: feeling of queasiness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: depression, mood changes, or suicidal thoughts. - Hepatic enzyme elevations: abnormal liver function tests.

When prescribing Montelukast, clinicians should consider several safety measures.

- Monitor liver function: periodic testing is advised for patients with hepatic disease. - Assess neuropsychiatric status: watch for mood changes or depressive symptoms. - Use caution in severe renal impairment: dosage adjustment may be required. - Avoid in patients with known hypersensitivity to montelukast or other leukotriene antagonists. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Montelukast may interact with other medicines; awareness of the interaction level helps guide therapy.

Major Interactions (Avoid): - Phenobarbital: induces metabolism and may reduce montelukast efficacy. - Ritonavir: strong CYP3A4 inhibition can increase montelukast plasma concentrations. - Concurrent leukotriene antagonists: no added therapeutic benefit and increased risk of adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Oral contraceptives: montelukast may reduce hormonal efficacy; consider alternative contraception. - Fluconazole: moderate CYP3A4 inhibition may modestly raise montelukast levels.